Evidence map›Paper›PMID 42355492›Full record

ArticleLife (Basel, Switzerland)2026

Heart-Type Fatty Acid-Binding Protein as a Marker of Subclinical Cardiac Dysfunction and Cardiorenal Interaction in Autosomal Dominant Polycystic Kidney Disease.

Bogdan D Agavriloaei, Stefan Iliescu, Gianina Dodi, Claudia M A Zaharie, Luminita E Voroneanu, Mugurel Apetrii, Călin Namolovan, Andreea S Covic, Cornel Moroșanu, Mehmet Kanbay and 1 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bogdan D AgavriloaeiGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Stefan IliescuGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Gianina DodiGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.ORCID 0000-0002-5551-6077
Claudia M A ZaharieDr. C.I. Parhon Clinical Hospital, 700503 Iasi, Romania.
Luminita E VoroneanuGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Mugurel ApetriiGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Călin NamolovanGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Andreea S CovicGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Cornel MoroșanuDr. C.I. Parhon Clinical Hospital, 700503 Iasi, Romania.
Mehmet KanbaySchool of Medicine, Koç University, 34450 Istanbul, Turkey.ORCID 0000-0002-1297-0675
Adrian C CovicGrigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.ORCID 0000-0002-9985-2486

Funding

Ministry of Research and Innovation PN-IV-P8-8.3-ROMD-2023-0259
6 · The paper itself

Abstract

(1) Background: Cardiovascular disease represents the leading cause of morbidity and mortality in patients with autosomal dominant polycystic kidney disease (ADPKD), often developing early in the disease course, even in the presence of preserved renal function. We aimed to evaluate circulating heart-type fatty acid-binding protein (H-FABP) as a marker of subclinical cardiac involvement and cardiorenal interaction in ADPKD. (2) Methods: In this single-center observational study, 80 adult patients with ADPKD receiving tolvaptan therapy were evaluated using echocardiography, renal function parameters, and circulating H-FABP levels. Associations between H-FABP and echocardiographic indices of cardiac structure and function, as well as renal parameters, were assessed using linear regression models. In addition, a composite severity score integrating CKD stage and H-FABP levels was constructed to assess the combined cardiorenal burden. (3) Results: Higher H-FABP concentrations were significantly associated with echocardiographic markers suggestive of subclinical cardiac involvement, particularly parameters related to impaired myocardial relaxation, including lower E/A ratio and reduced tissue Doppler e' velocities. These associations remained significant after adjustment for renal function and relevant clinical covariates. In parallel, H-FABP levels were also associated with markers of renal disease severity, including lower baseline eGFR and greater total kidney volume. The composite severity score showed a graded association with echocardiographic parameters, with a progressive trend toward less favorable diastolic indices as risk categories increased. These findings suggest a potential complementary role for H-FABP in the integrated evaluation of cardiorenal involvement in ADPKD. Given the cross-sectional design and single-centre setting, these results should be considered hypothesis-generating and require prospective validation in larger, independent cohorts.

Indexed as

autosomal dominant polycystic kidney diseasecardiovascular diseasecardiovascular riskH-FABP

Identifiers

PMID42355492
PMCPMC13301678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.